JP MORGAN/CALL/BECTON DICKINSON AND CO./270/0.1/21.06.24 Share Price

Warrant

DE000JB0XYN2

Real-time Bid/Ask 09:19:36 03/06/2024 BST
0.036 EUR / 0.34 EUR +1,346.15% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./270/0.1/21.06.24
1 month-90.00%
3 months-97.64%
Date Price Change
03/06/24 0.042 +223.08%
31/05/24 0.013 +550.00%
30/05/24 0.002 +100.00%
29/05/24 0.001 -75.00%
28/05/24 0.004 +33.33%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 07:43 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JB0XYN
ISINDE000JB0XYN2
Date issued 22/08/2023
Strike 270 $
Maturity 21/06/2024 (19 Days)
Parity 10 : 1
Emission price 2.71
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.3
Lowest since issue 0.001
Spread 0.303
Spread %89.12%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232 USD
Average target price
278.7 USD
Spread / Average Target
+20.14%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW